Journal Information
Vol. 39. Issue 1.
Pages 1-8 (January - March 2019)
Download PDF
More article options
Vol. 39. Issue 1.
Pages 1-8 (January - March 2019)
Original Article
Open Access
Validation of Portuguese version of the low anterior resection syndrome score
Validação da versão em português do escore da síndrome da ressecção anterior baixa
Nuno José Ramaa,b,
Corresponding author

Corresponding author.
, Pedro Lopes Ferreirac,d, João Pimentele,f, Therese Juulg, Portuguese PT LARS Collaborative Group
a Centro Hospitalar de Leiria, Centro Colorretal, Leiria, Portugal
b Universidade do Porto, ICBAS, Porto, Portugal
c Universidade de Coimbra, Faculdade de Economia, Coimbra, Portugal
d Universidade de Coimbra, Centro de Estudos e Investigação em Saúde (CEISUC), Coimbra, Portugal
e Centro Hospitalar e Universitário de Coimbra, Centro Colorretal, Coimbra, Portugal
f Universidade de Coimbra, Faculdade de Medicina, Coimbra, Portugal
g Aarhus University Hospital, Department of Surgery P, Aarhus, Denmark
Article information
Full Text
Download PDF
Tables (5)
Table 1. Sociodemographic and clinical sample characteristics.
Table 2. Quality of life scores.
Table 3. Reliability scores.
Table 4. Sociodemographic and clinical determinants of LARS scores.
Table 5. Criterion validity of LARS.
Show moreShow less

The authors aim to perform a thorough translation with cultural adaptation of the patient reported outcome tool, Low Anterior Resection Syndrome (LARS) Score, to the Portuguese language (LARS-PT) in the Portuguese population with rectal cancer, after proctectomy with anastomosis.


According to the current international recommendations, we designed this study encompassing three main phases: (i) cultural and linguistic validation to European Portuguese; (ii) feasibility and reliability tests of the version obtained in the previous phase; and (iii) validity tests to produce a final version. The questionnaire was completed by 154 patients from six Portuguese Colorectal Cancer Units, and 58 completed it twice.


Portuguese version of LARS score showed high construct validity. Regarding the test-retest, the global Intraclass Correlation showed very strong test-retest reliability. Looking at all five items, only items 3 and 5 present a moderate correlation. LARS score was able to discriminate symptoms showing worse quality of life, in patients submitted to preoperative radio and chemotherapy.


LARS questionnaire has been properly translated into European Portuguese, demonstrating high construct validity and reliability. This is a precise, reproducible, simple, clear and user-friendly tool for evaluating bowel function in rectal cancer patients after sphincter saving operation.

Rectal neoplasms
Bowel dysfunction
Low anterior resection syndrome score
Quality of life

Os autores pretendem fazer uma tradução minuciosa e culturalmente adaptada para a língua portuguesa do escore da Síndrome de Ressecção Anterior Baixa (Low Anterior Resection Syndrome [LARS]), um instrumento de desfecho relatado pelo paciente, na população portuguesa com câncer retal após proctectomia com anastomose.


De acordo com as recomendações internacionais atuais, o estudo foi projetado abrangendo três fases principais: (i) validação cultural e linguística para o português europeu; (ii) testes de viabilidade e confiabilidade da versão obtida na fase anterior; e (iii) testes de validade para produzir a versão final. O questionário foi preenchido por 154 pacientes de seis unidades portuguesas de câncer colorretal e 58 pacientes completaram duas vezes.


A versão em português do escore LARS mostrou alta validade de construto. A correlação intra-classe global apresentou confiabilidade muito forte no teste-reteste. Considerando-se todos os cinco itens, apenas os itens 3 e 5 apresentam uma correlação moderada. O escore LARS foi capaz de discriminar sintomas com pior qualidade de vida em pacientes submetidos a radio- e quimioterapia pré-operatória.


O questionário LARS foi traduzido corretamente para o português europeu, demonstrando alta validade de construto e confiabilidade. Trata-se de uma ferramenta precisa, reproduzível, simples, clara e fácil de usar para avaliar a função intestinal em pacientes com câncer retal após operações poupando o esfíncter.

Neoplasias retais
Disfunção intestinal
Escore da síndrome da ressecção anterior baixa
Qualidade de vida
Full Text

Colorectal cancer is the third most frequent diagnosed malignancy followed by prostate in males, breast in females, and by lung cancer in both genders.1,2 On this matter, one out of three are located in the rectum, one-third on its distal part, and approximately half of patients die from their cancer.3,4 The incidence and mortality rates vary according to distinct gradients of human development levels, presenting a stabilizing or decreasing trend in highly developed countries, where rates remain amongst the highest in the world.1

During the last decades, several improvements in Rectal Cancer (RC) treatment were achieved, but surgery remains the favoured form of treatment. These developments have resulted in markedly increased survival.5 A tailored treatment was possible since the introduction of routine accurate high-resolution preoperative RC imaging and the standardized proctectomy with Total Mesorectal Excision (TME).6

Nowadays, not only oncological outcomes are relevant for colorectal surgeons, but also long-term functional outcomes and Quality of Life (QoL). Knowledge about functional gastrointestinal and genitourinary patient-reported outcomes are crucial in order to select the optimal treatment and to manage functional sequela.7,8 Despite the rectal reconstruction technique and the use of neoadjuvant therapy, 60% to 90% of patients undergoing proctectomy develop some sort of bowel dysfunction.9,10

The syndrome of defecatory dysfunction that occurs after proctectomy, also called “Low Anterior Resection Syndrome (LARS)”, is a constellation of symptoms, with variable incidence and degrees, which includes increased bowel frequency, urgency, fragmentation, faecal incontinence, nocturnal defecation, difficulty in discriminating between gas and stools, and incomplete evacuation.8,11–13

Several measurement instruments have been used to evaluate bowel dysfunction after anterior resection, but mostly are focused on the incontinence aspect of LARS.14–18 One of the drawbacks of these tools was the fact that they are based on a linear scale, and the impact on QoL might not be so foreseeable and linear. Additionally these scores only look into one facet of LARS, not considering it as a complex dysfunction.

Recently, Emmertsen and Laurberg developed and validated a symptom-based scoring system, named LARS score that takes into account four aspects of bowel function.19 This quick, simple and user-friendly self-administered questionnaire objectively measures patient symptoms, and provides information for the LARS management. It consists of five simple questions regarding incontinence for flatus or liquid stool, urgency, clustering and frequency. Scored according to the impact of each of these symptoms in patients’ QoL, they are weighted and presented in a summative score ranging from 0 to 42. Patients are ranked into three severity groups: no LARS (0–20 points), minor LARS (21–29 points) and major LARS (30–42 points). Until now, this score has been translated and validated in several languages, worldwide.11,13,20,21

The aim of our study was to perform a thorough translation with cultural adaptation of this patient-reported outcome tool (LARS score) to the European Portuguese language (LARS-PT). We assessed its psychometric properties in a Portuguese sample, in order to build up and validate a suitable tool for daily clinical practice and research in Portugal.


This study encompassed three main phases: (i) cultural and linguistic validation to European Portuguese; (ii) feasibility and reliability tests of the version obtained in the previous phase; and (iii) validity tests to produce a final version.

After obtaining a written permission from the original author, we followed the forward/backward translation process.22 The English version of the LARS score was then initially translated into Portuguese by two independent professional translators whose mother tongue was Portuguese. Our group discussed any conceptual discrepancies between the two versions, and we reached a final consensus, the preliminary Portuguese version. A third independent English translator, unfamiliar with the background objectives of the study, then performed a back-translation of this version.

After comparing the original and the backward versions, the investigators revised, checked and agreed upon the Portuguese version. For the face validation process, two clinicians revised this new version and some changes were made accordingly. In addition, a cognitive debriefing sample of ten patients with low literacy level were selected from two participating centres, in order to assess its feasibility, comprehensiveness, length, adequacy, redundancy and text clarity. The final version of LARS-PT was linguistically reviewed to correct possible grammatical errors.

The participants involved were recruited from six Portuguese hospitals, with colorectal cancer units (CRCU), between November 2016 and June 2017. Our study comprised voluntary patients operated for RC, over 18 years old that had undergone either a curative total or Partial Mesorectal Excision (PME), from January 1, 2005 to April 30, 2015. We established a minimum duration of fourteen months after surgery to allow their bowel function to have regained stability. Patients were excluded if they had stoma, disseminated or recurrent disease, any type of bowel dysfunction not related to RC treatment (inflammatory bowel disease, irritable bowel syndrome, amongst others), or mental health problems.

Eligible participants were identified through local medical records of RC patients by the local investigators at each of the participating centres and the patients to be approached were selected randomly from the pool of eligible subjects. The six local clinical researchers collected demographic and clinical information from local databases. Patients received the LARS-PT questionnaire along with an invitation to participate in the study. In addition, we also administered the Portuguese versions of the two quality of life measures EORTC QLQ-C30 and EQ-5D-5L, and a separate “bothersome” question also aiming to assess their QoL (“Overall, how much does your bowel function affect your quality of life?”). The answers from the “bothersome” question were classified according to the inconvenience, where 1 is none and 5–7 is extremely inconvenient.

In most of CRCU, patients who had a T3 tumour with a threatened circumferential margin or T4 tumour (any N) were submitted to neoadjuvant long-course chemoradiotherapy. Moreover, in some CRCU, patients with T3 (any N) cancer or T1 or T2 cancer with node positive underwent short-course radiotherapy (5×5Gy) before surgery. The operative procedure included midline laparotomy or minimally invasive approach, high ligation of the inferior mesenteric vessels, mobilization of the splenic flexure, and colorectal resection with standard TME or PME (depending on the tumour location). All the patients included in the study had negative distal and circumferential margins on histological examination.

In our study, we tested the temporal stability by a randomized subgroup of patients and asked them to fill the LARS-PT questionnaire, between one to two weeks after the completion of the first round. The interviews were face-to-face or by phone, depending upon the local facilities and the resources available. We excluded any retest if the time gap between the completions of both tests was outside the predefined acceptable interval of one to twelve weeks. Furthermore, we did not consider for test-retest analysis, patients who had mentioned a relevant change in bowel function in the revaluation period. Intraclass Correlation Coefficient (ICC) was used and was considered significant if higher than 0.7.23

It includes the analysis of the content validity, the construct validity and the criteria validity. The cultural and linguistic adaptation process guarantees the content validity. The construct validity tests whether the theoretical framework of the measurement instrument is confirmed by the Portuguese version. This includes hypotheses regarding known sociodemographic and clinical variables, as well as the correlations with a measurement instrument that measures similar concepts. The criterion validity represents the degree of agreement between the measurement instrument and another reference measure. In this study, we used the previously referred bothersome question.

In this study, all statistical analyses were performed using SPSS v22, considering a significance level of 0.05.

Demographic and clinical variables were analyzed by using descriptive statistics. For comparative analyses, we used nonparametric tests, namely, Mann–Whitney U and Kruskal–Wallis H tests.

To evaluate the criterion validity, Chi-squared test was used to test the independence between these variables and the LARS classified score.


Both translations of LARS demonstrated minor discrepancies easily solved, and discussion of the back translation corroborated the original meaning of the five questions. Cognitive debriefing involved six males and four females, seven aged 65 or more, and all of them with medium to low education. None of the ten patients revealed difficulties in understanding the items. This guaranteed the content validity of this measure. The final Portuguese version can be found in

From November 2016 to June 2017, 154 patients answered the questionnaire LARS-PT. Demographic and clinical information obtained by the six local clinical researchers is presented in Table 1.

Table 1.

Sociodemographic and clinical sample characteristics.

  Variable  n 
Participants    154  100.0 
GenderMale  89  57.9 
Female  65  42.1 
Age (years)<65 years  60  39.0 
65–74 years  46  29.9 
>75 years  48  31.2 
Mean±SD  68.1±10.9   
Min–max  36–89   
Family statusMarried  126  82.9 
Single  3.3 
Widow  13  8.6 
Divorced/separated  5.3 
Labour statusActive  38  25.7 
Non-active  110  74.3 
EducationLess than basic  14  9.2 
Basic (years 1–9)  100  65.8 
Secondary (years 10–12)  18  11.8 
Higher  20  13.2 
Stage, TNM38  28.8% 
II  24  18.2% 
III  70  53.0% 
Tumour localizationUpper third  45  31.0% 
Middle third  76  52.4% 
Lower third  24  16.6% 
Type of anastomosisMechanic  136  94.4% 
Manual  5.6% 
Neoadjuvant radiotherapyYes  71  49.0% 
No  74  51.0% 
Length of the postoperative period<3 years  63  44.1% 
≥3 years  80  55.9% 
Mean±SD  10.3±3.7   
Min–max  0.0–10.3   
Type of surgeryTME  97  71.3% 
PME  39  28.7% 
LARS scoreNo LARS  52  34.2% 
Minor LARS  37  24.3% 
Major LARS  63  41.4% 
Mean±SD  23.9±12.4   
Min–max  0–42   

From Table 1, is evident that our sample had a slight majority (57.9%) of male patents, only 39.0% of the patients had less than 65 years of age, the majority were married (82.9%), professionally non-active (74.3%), and with less than ten years of education (75.0%).

Their tumour was mainly in Stage III (53.1%) and located in the middle third (52.4%), half underwent neo-adjuvant therapy (51.0%) and the mean length of the postoperative period was about 10 years. The type of mesorectal excision was mainly (71.3%) TME.

LARS scores ranged between 0 and 42 with a mean value of 23.9±12.4, a little bit more than one-third (34.2%) with no LARS, 24.3% with minor LARS and 41.8% with major LARS.

Moreover, Table 2 presents the description of the quality of life indicators of our sample.

Table 2.

Quality of life scores.

QoL measure  Dimension  Min  Max  Mean  SD 
EORTC-QLQ-C30  Physical function  0.0  100.0  83.7  19.6 
Functional scalesRole physical  0.0  100.0  85.9  24.9 
Emotional function  25.0  100.0  85.9  16.9 
Cognitive function  16.7  100.0  86.1  17.0 
Social function  0.0  100.0  86.7  22.0 
EORTC-QLQ-C30  Fatigue  0.0  88.9  18.0  21.1 
Symptom scalesNausea and vomiting  0.0  50.0  1.2  6.9 
Pain  0.0  100.0  14.9  22.1 
Dyspnoea  0.0  66.7  1.5  8.0 
Sleep disturbance  0.0  100.0  18.5  25.6 
Appetite loss  0.0  66.7  5.0  14.7 
Constipation  0.0  100.0  11.1  20.2 
Diarrhoea  0.0  100.0  12.4  20.9 
Financial impact  0.0  100.0  9.8  19.8 
Quality of life  16.7  100.0  73.3  19.0 
EQ-5D-5LIndex  16  1.00  0.90  0.16 
VAS  10  100.0  74.5  0.19 

From Table 2 we notice that, in general, the patients of this study felt a very good quality of life. This is evident from the EORTC-QLQ-C30 functional scales with mean scores between 83.7 and 86.7, from the quality of life questions with a mean of 73.3, and from both index and VAS scale with mean values, respectively, 0.90 and 74.5. Corroborating with these results, and looking at the intensity of the symptoms, we evidence only a light disturbance from sleep, fatigue, pain, diarrhoea and constipation.

Regarding the test-retest, 58 patients repeated the LARS questionnaire, up to three weeks after the completion of the first questionnaire. Table 3 shows the reliability scores.

Table 3.

Reliability scores.

Items  ICC  95% CI 
Item 1  0.763  0.600–0.860 
Item 2  0.863  0.769–0.919 
Item 3  0.652  0.413–0.794 
Item 4  0.761  0.596–0.859 
Item 5  0.669  0.441–0.804 
LARS total score  0.864  0.771–0.920 

ICC, Intraclass Correlation; CI, Confidence Interval.

The global ICC shows very strong test-retest reliability. Looking at all five items, only items 3 and 5 present a moderate correlation.


To test the construct validity of LARS we looked at the sociodemographic and clinical variables. The results of the tests are presented in Table 4.

Table 4.

Sociodemographic and clinical determinants of LARS scores.

Hypothesis  Variable  Value  Mean rank  Statistics  Sig. 
H1GenderMale  73.7  U=25680.354
Female  80.4 
H2Age (years)<65 years  84.3  H=3.3590.186
65–74 years  78.1 
>75 years  68.5 
H3Family statusMarried  76.8  U=15990.849
Non-married  75.0 
H4Labour statusActive  74.5  U=20880.993
Non-active  74.5 
H5Neoadjuvant radiotherapyYes  81.5  U=20220.017
No  64.8 
H6AnastomosisMechanic  69.8  U=1840.002
Manual  117.5 
H7Length of the postoperative period≤2 years  69.2  U=14060.622
>2 years  73.8 
H8Type of surgeryTME  70.3  U=17180.405
PME  64.1 

U, Wilcoxon W; H, Kruskal–Wallis H; Sig, asymptotic Sig (2 tailed).

Looking at the results from Table 4, we can notice that the sociodemographic variables (gender, age, family status, and labour status) do not have any influence on the LARS final score. In addition, the length of the postoperative period seems to not have any influence on LARS sores. On the contrary, having neo-adjuvant radiotherapy increases LARS scores.

Still addressing construct validity, we looked at the correlations between LARS scores and the various dimensions of EORTC QLQ-C30 as well as EQ-5D-5L index and the EQ-5D-VAS. The results of the corresponding correlation coefficients are presented in Table 5.

Table 5.

Criterion validity of LARS.

QoL measure  Dimension  LARS scores  p-value 
EORTC-QLQ-C30  Physical function  −0.116  0.153 
Functional scalesRole physical  −0.125  0.123 
Emotional function  −0.131  0.105 
Cognitive function  −0.122  0.134 
Social function  −0.163  0.044 
EORTC-QLQ-C30  Fatigue  0.130  0.110 
Symptom scalesNausea and vomiting  0.062  0.448 
Pain  0.206  0.011 
Dyspnoea  0.015  0.856 
Sleep disturbance  0.086  0.289 
Appetite loss  −0.054  0.507 
Constipation  0.073  0.367 
Diarrhoea  0.353  0.000 
Financial impact  0.189  0.020 
Quality of life  −0.150  0.064 
EQ-5D-5LIndex  −0.116  0.153 
VAS  −0.089  0.274 

From Table 5, as expected, we can see that the major correlation resides on the dimension ‘social function’ of the EORTC QLQ-C30's functional scales and, mainly on the symptoms pain, and diarrhoea. Financial impact also showed to have a very significant correlation on LARS scores. On the other hand, quality of life showed a very small correlation and EQ-5D-5L was unable to find any significant correlation with the LARS score.

Finally, the independence test between “bothersome” question and the classified LARS scores revealed a Chi-squared statistics of X2=16.8 (α=0.002) showing that LARS classification is coherent with how much bowel function affects quality of life. That is, individuals who reported no bother at all, also had a LARS score less than or equal to 20, meaning no LARS. On the other hand, individuals with major LARS were the ones that mentioned their QoL being largely affected by bowel function.


Historically, the most relevant outcomes in RC management were mortality and local recurrence, but currently, the evaluation of functional results and QoL of the patients submitted to LAR is a matter of great importance.

Dysfunctions after proctectomy, mainly in LAR, occur in a great number of patients, and affect not only the bowel function but also the genitourinary function, in high figures, up to 70 or even 90%, when we look to bowel dysfunction. These symptoms often arise immediately after surgery and may decrease over the months, reaching a plateau within the first two years.24 In fact, up to 80% of patients undergoing a LAR or a very LAR will experience postoperatively a constellation of symptoms collectively referred as LARS.5,25 Although most of the functional impairments are clinically recovered in the first year after the proctectomy, long-term studies are now reporting the presence of adverse symptoms up to 15 years after resection.20,26

LARS score, despite being considered user-friendly, had not been tested in the Portuguese population, yet. Our group followed a rigorous protocol in accordance with current international recommendations, similar to that used in the international validation of the LARS score by Juul et al., to ensure semantic equivalence among different languages and to enable the use in different populations worldwide.20,21,27 We developed this research in six CRUC with patients coming from five public health system institutions and one private hospital. With this method, we guarantee an adequate, balanced national representativeness, including patients with low educational and income levels. None of them exhibited difficulty to understand the items of the questionnaire during the cultural adaptation, proving the practical feasibility of this tool. Overall, we found a good compliance across all items, which demonstrate the user-friendliness of the LARS score.

In our study, LARS score was easily validated for the Portuguese population of patients with RC, and has shown concluding psychometric properties. Considering the construct validity, we have proved a strong association between the LARS-PT score and the self-reported QoL. Patients with poor QoL, due to impaired bowel function, demonstrated higher numerical values on LARS-PT questionnaire. Moreover, LARS-PT score presented a convergent agreement with overall health and with all EORTC QLQ-C30 functional scales, showing that patients with worse LARS classification have lower QoL reported by EORTC QLQ-C30.

The current study provided some evidence for the good discriminate validity of the measures. That is clearly highly important, since the utility of the LARS-PT score would be hampered without the ability to discriminate between patients with different clinical characteristics, known to diverge in terms of LARS symptoms. In this topic, the Portuguese version of LARS score was able to identify groups with worse intestinal functional outcomes after LAR. Known variables such as gender, age, level of the tumour, preoperative therapy, type of procedure (TME vs. PME), temporary diverting stoma and postoperative period length could impair gastrointestinal function after sphincter saving surgery in RC population.5,24,28 LARS-PT score showed ability to detect differences between patients submitted or not to neo-adjuvant treatment. In our study, we did not prove that LARS symptoms improve with time. By contrast, there were no statistically significant differences related with gender, age, family status or labour status.

Also criterion validity tested with the bothersome question showed that LARS classification is coherent with how much bowel function affects quality of life (X2=16.8; p=0.002).

The evaluation of test-retest reliability of LARS-PT score was done from a sample of 58 patients, with the interval between the two surveys ranging from 10 to 21 days. This interval was deemed appropriate, as it avoids not only the first survey effect but also the changes in bowel function, even though participants who reported a significant change in bowel function between the tests were excluded. After repeating the evaluation, no differences were registered in LARS-PT questions and score. The global ICC estimated (ICC=0.864) demonstrates a very strong test-retest reliability, and when we look at all five items, only items 3 and 5 present a moderate correlation (ICC of 0.652 and 0.669, respectively).

Limitations of this study were the small sample size and its retrospective observational nature, mainly the fact that the anorectal function was not assessed before surgery. The preoperative use of LARS score and the regular surveillance in the early and late postoperative period may contribute to clarifying some aspects of LARS pathophysiology. Some preoperative factors, like neo-adjuvant therapies, gender, age or tumour location, may affect postoperative function, so it is crucial to guide an appropriate preoperative discussion outlining risk and options. The question is: “Can we predict bowel function before proctectomy?” Recently, Battersby et al. developed the POLARS score, and with this instrument, patients with RC can be preoperatively informed of their likely postoperative bowel function, based on the LARS scores evaluation.29 Additionally it can be used as an adjunct for clinical assessment prior to the multidisciplinary team discussion, helping to guide treatment decisions.

This study has the advantage of having compared the LARS score with a validated general and symptoms-based QoL instruments such as EQ-5D-5L and EORTC QLQ-C30. As we abovementioned, the majority of instruments used to assess bowel function after LAR, measure only faecal incontinence, omitting other symptoms at least so relevant, and with high correlation with QoL, such as urgency or clustering. These symptoms are most closely correlated with QoL, in a patient-centred perspective. Validation of this tool enables the dissemination of the measurement of bowel function after LAR, employing a quick and comprehensive clinically applicable instrument. Therefore, it will help clinicians to understand the impact of LARS symptoms in QOL, from the patient viewpoint.10,26,29

In conclusion, LARS questionnaire has been properly translated into Portuguese, demonstrating high construct validity and reliability. Our LARS version is a precise, reproducible, simple, clear and user-friendly tool for evaluating bowel function in RC patients after sphincter saving operation. Thereby should be systematically applied for both clinical and research settings.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the Portuguese ethical standards: Authorization was obtained from the Portuguese Data Protection Authority (CNPD) and Local Ethical Committee approval. Informed consent was obtained from all patients included in the study.

Conflicts of interest

The authors declare no conflicts of interest.

Appendix A
Portuguese LARS collaborative group

Portuguese LARS Collaborative Group includes:

Writing group: N. Rama, P.L. Ferreira, J. Pimentel and T. Jull.

Local Researchers:

Centro Hospitalar de Leiria: N. Rama, P. Alves, P. Clara, S. Amado, I. Gil, I. Sales

Centro Hospitalar e Universitário de Coimbra: J. Pimentel

Champalimaud Foundation: N. Figueiredo, H. Domingos, P. Vieira

IPO Lisboa: M. Limbert, J. Maciel

Hospital Distrital de Santarém: N. Vilela, L. Ferreira, O. Oliveira

Hospital de Braga: P. Leão, A. Goulart, M. Sousa.

M. Arnold, M.S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray.
Global patterns and trends in colorectal cancer incidence and mortality.
Gut, 66 (2017), pp. 683-691
Y. Ziv, A. Zbar, Y. Bar-Shavit, I. Igov.
Low anterior resection syndrome (LARS): cause and effect and reconstructive considerations.
Tech Coloproctol, 17 (2013), pp. 151-162
V. Valentini, R. Beets-Tan, J. Borras, Z. Krivokapic, J. Leer, L. Pahlman, et al.
Evidence and research in rectal cancer.
Radiother Oncol, 87 (2008), pp. 449-474
M. Riihimäki, A. Hemminki, J. Sundquist, K. Hemminki.
Patterns of metastasis in colon and rectal cancer.
K.J. Emmertsen, T.Y.-T. Chen, S. Laurberg.
Functional results after treatment for rectal cancer.
J Coloproctol (Rio J), 34 (2014), pp. 55-61
R.J. Heald, E.M. Husband, R.D. Ryall.
The mesorectum in rectal cancer surgery – the clue to pelvic recurrence?.
Br J Surg, 69 (1982), pp. 613-616
L. Desnoo, S. Faithfull.
A qualitative study of anterior resection syndrome: the experiences of cancer survivors who have undergone resection surgery.
Eur J Cancer Care, 15 (2006), pp. 244-251
T. Juul, N.J. Battersby, P. Christensen, A.Z. Janjua, G. Branagan, S. Laurberg, et al.
Validation of the English translation of the low anterior resection syndrome score.
Colorectal Dis, 17 (2015), pp. 908-916
R. Kakodkar, S. Gupta, S. Nundy.
Low anterior resection with total mesorectal excision for rectal cancer: functional assessment and factors affecting outcome.
Colorectal Dis, 8 (2006), pp. 650-656
C. Keane, C. Wells, G. O’Grady, I.P. Bissett.
Defining low anterior resection syndrome: a systematic review of the literature.
Colorectal Dis, 19 (2017), pp. 713-722
Hou X.-t., D. Pang, Q. Lu, P. Yang, S.-l. Jin, Y.-j. Zhou, et al.
Validation of the Chinese version of the low anterior resection syndrome score for measuring bowel dysfunction after sphincter-preserving surgery among rectal cancer patients.
Eur J Oncol Nurs, 19 (2015), pp. 495-501
Y. Ribas, F. Aguilar, E. Jovell-Fernandez, L. Cayetano, A. Navarro-Luna, A. Munoz-Duyos.
Clinical application of the LARS score: results from a pilot study.
Int J Colorectal Dis, 32 (2017), pp. 409-418
N.E. Samalavicius, A. Dulskas, M. Lasinskas, G. Smailyte.
Validity and reliability of a Lithuanian version of low anterior resection syndrome score.
Tech Coloproctol, 20 (2016), pp. 215-220
F. de la Portilla, A. Calero-Lillo, R.M. Jiménez-Rodríguez, M.L. Reyes, M. Segovia-González, M.V. Maestre, et al.
Validation of a new scoring system: rapid assessment faecal incontinence score.
World J Gastrointest Surg, 7 (2015), pp. 203-207
J.M. Jorge, S.D. Wexner.
Etiology and management of fecal incontinence.
Dis Colon Rectum, 36 (1993), pp. 77-97
T.H. Rockwood, J.M. Church, J.W. Fleshman, R.L. Kane, C. Mavrantonis, A.G. Thorson, et al.
Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence: the fecal incontinence severity index.
Dis Colon Rectum, 42 (1999), pp. 1525-1532
C. Vaizey, E. Carapeti, J. Cahill, M. Kamm.
Prospective comparison of faecal incontinence grading systems.
Gut, 44 (1999), pp. 77-80
N.S. Williams, J. Patel, B.D. George, R.I. Hallan, E.S. Watkins.
Development of an electrically stimulated neoanal sphincter.
Lancet (London, England), 338 (1991), pp. 1166-1169
K.J. Emmertsen, S. Laurberg.
Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer.
Ann Surg, 255 (2012), pp. 922-928
T. Juul, M. Ahlberg, S. Biondo, K.J. Emmertsen, E. Espin, L.M. Jimenez, et al.
International validation of the low anterior resection syndrome score.
Ann Surg, 259 (2014), pp. 728-734
K. Buzatti.
Validação para a Língua Portuguesa do Escore “LARS” de avaliação da Síndrome Pós-ressecção Anterior do Reto [Dissertation]..
Universidade Federal de Minas Gerais, (2016),
D. Wild, A. Grove, M. Martin, S. Eremenco, S. McElroy, A. Verjee-Lorenz, et al.
Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.
Value Health, 8 (2005), pp. 94-104
C.B. Terwee, S.D. Bot, M.R. de Boer, D.A. van der Windt, D.L. Knol, J. Dekker, et al.
Quality criteria were proposed for measurement properties of health status questionnaires.
J Clin Epidemiol, 60 (2007), pp. 34-42
J.I. Bleier, J.A. Maykel.
Outcomes following proctectomy.
Surg Clin North Am, 93 (2013), pp. 89-106
C.L. Bryant, P.J. Lunniss, C.H. Knowles, M.A. Thaha, C.L. Chan.
Anterior resection syndrome.
Lancet Oncol, 13 (2012), pp. e403-e408
T.Y. Chen, K.J. Emmertsen, S. Laurberg.
Bowel dysfunction after rectal cancer treatment: a study comparing the specialist's versus patient's perspective.
BMJ Open, 4 (2014), pp. e003374
Kuliś D, Bottomley A, Velikova G, Greimel E, Koller M. EORTC quality of life group translation procedure: EORTC; 2017 [updated 19 January 2017. 4:26]. Available from:
P. Campelo, E. Barbosa.
Functional outcome and quality of life following treatment for rectal cancer.
J Coloproctol (Rio J), 36 (2016), pp. 251-261
N.J. Battersby, G. Bouliotis, K.J. Emmertsen, T. Juul, R. Glynne-Jones, G. Branagan, et al.
Development and external validation of a nomogram and online tool to predict bowel dysfunction following restorative rectal cancer resection: the POLARS score.
Journal of Coloproctology

Subscribe to our newsletter

Article options